Cantargia AB (publ) (STO:CANTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
2.745
+0.115 (4.37%)
Aug 29, 2025, 5:29 PM CET
4.37%
Market Cap682.44M
Revenue (ttm)n/a
Net Income (ttm)-167.61M
Shares Out248.61M
EPS (ttm)-0.78
PE Ration/a
Forward PE4.95
Dividendn/a
Ex-Dividend Daten/a
Volume2,921,762
Average Volume2,533,963
Open2.645
Previous Close2.630
Day's Range2.600 - 2.800
52-Week Range1.000 - 4.780
Beta1.55
RSI50.48
Earnings DateAug 21, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 22
Stock Exchange Nasdaq Stockholm
Ticker Symbol CANTA
Full Company Profile

Financial Performance

Financial Statements

News

Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates

Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates

10 months ago - GuruFocus

Q3 2024 Cantargia AB Earnings Call Transcript

Q3 2024 Cantargia AB Earnings Call Transcript

10 months ago - GuruFocus